Vest Financial LLC Has $67.52 Million Stock Holdings in AbbVie Inc. $ABBV

Vest Financial LLC trimmed its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 1.4% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 268,319 shares of the company’s stock after selling 3,946 shares during the quarter. Vest Financial LLC’s holdings in AbbVie were worth $67,520,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. Brighton Jones LLC lifted its holdings in shares of AbbVie by 17.4% in the fourth quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock valued at $4,072,000 after purchasing an additional 3,401 shares in the last quarter. Revolve Wealth Partners LLC grew its holdings in shares of AbbVie by 72.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock worth $1,294,000 after buying an additional 3,064 shares in the last quarter. Schnieders Capital Management LLC. raised its position in AbbVie by 5.0% in the 2nd quarter. Schnieders Capital Management LLC. now owns 16,466 shares of the company’s stock valued at $3,056,000 after buying an additional 789 shares during the last quarter. Ieq Capital LLC raised its position in AbbVie by 4.6% in the 2nd quarter. Ieq Capital LLC now owns 120,035 shares of the company’s stock valued at $22,281,000 after buying an additional 5,274 shares during the last quarter. Finally, Worldquant Millennium Advisors LLC lifted its stake in AbbVie by 117.3% in the 2nd quarter. Worldquant Millennium Advisors LLC now owns 1,135,034 shares of the company’s stock valued at $210,685,000 after acquiring an additional 612,702 shares in the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the transaction, the executive vice president owned 74,430 shares of the company’s stock, valued at $18,607,500. This trade represents a 30.53% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.06% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several equities analysts have recently weighed in on ABBV shares. DZ Bank raised shares of AbbVie from a “hold” rating to a “strong-buy” rating in a research note on Thursday, April 30th. BNP Paribas Exane boosted their price objective on shares of AbbVie from $218.00 to $247.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 11th. Wells Fargo & Company increased their target price on shares of AbbVie from $295.00 to $300.00 and gave the stock an “overweight” rating in a report on Monday. Citigroup raised their target price on shares of AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a research report on Wednesday, July 15th. Finally, Piper Sandler reissued an “overweight” rating and set a $298.00 price target on shares of AbbVie in a research report on Tuesday, June 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $275.73.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie completed a multibillion-dollar senior notes offering to help finance its acquisition of Apogee Therapeutics. The transaction provides funding for the deal and supports AbbVie’s strategy of expanding its immunology and specialty medicines portfolio as it seeks new growth opportunities. AbbVie Completes $10 Billion Senior Notes Offering to Support Apogee Therapeutics Acquisition AbbVie Raises $9 Billion Debt to Fund Acquisition
• Neutral Sentiment: The Apogee financing also introduces additional leverage. While debt allows AbbVie to pursue the acquisition without issuing equity, investors will assess the impact of higher interest costs and whether Apogee’s pipeline generates sufficient returns to justify the transaction. AbbVie Completes $10 Billion Senior Notes Offering to Support Apogee Therapeutics Acquisition
• Neutral Sentiment: AbbVie announced its 2026 Immunology Scholarship recipients, continuing a 10-year community-support program. The announcement reinforces corporate reputation but is unlikely to materially affect earnings or the stock’s near-term valuation. AbbVie Announces 2026 AbbVie Immunology Scholarship Recipients
• Negative Sentiment: Executive Vice President Nicholas Donoghoe sold 32,710 ABBV shares for approximately $8.18 million, reducing his holdings by about 30.5%. Insider sales can reflect personal financial planning, but the sizable transaction may create a modest negative sentiment signal for investors. AbbVie Insider Transaction

AbbVie Stock Up 2.6%

NYSE:ABBV opened at $265.63 on Thursday. AbbVie Inc. has a twelve month low of $190.75 and a twelve month high of $267.47. The firm has a market capitalization of $469.31 billion, a price-to-earnings ratio of 75.04, a price-to-earnings-growth ratio of 0.86 and a beta of 0.30. The stock’s 50 day moving average price is $246.98 and its two-hundred day moving average price is $226.95.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, July 31st. The company reported $3.65 EPS for the quarter, beating the consensus estimate of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The company had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. During the same quarter in the prior year, the firm posted $2.97 EPS. The firm’s revenue for the quarter was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, analysts anticipate that AbbVie Inc. will post 14.07 earnings per share for the current year.

AbbVie Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th were paid a $1.73 dividend. The ex-dividend date was Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.6%. AbbVie’s dividend payout ratio (DPR) is currently 195.48%.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.